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MaBACKGROUND Cardiosphere-derived cells mediate therapeutic regeneration in patients after myocardial infarction and
are undergoing further clinical testing for cardiomyopathy. The beneﬁcial effects of cardiosphere-derived cells are
mediated by the secretion of exosomes and possibly other extracellular membrane vesicles (EMVs).
OBJECTIVES This study sought to investigate the effect of cardiosphere-derived EMVs (CSp-EMVs) on ﬁbroblasts
in vitro and tested whether priming with CSp-EMVs could confer salutary properties on ﬁbroblasts in vivo.
METHODS CSp-EMVs were isolated from serum-free media conditioned for 3 days by cardiospheres. Dermal ﬁbroblasts
were primed with CSp-EMVs for 24 h followed by exosomal micro-ribonucleic acid proﬁling. In vivo, we injected CSp-
EMVprimed or unprimed dermal ﬁbroblasts (or CSp-EMVs) in a chronic rat model of myocardial infarction and deﬁned
the functional and structural consequences.
RESULTS CSp-EMVs ampliﬁed their own biological signals: exposure of “inert” ﬁbroblasts to CSp-EMVs rendered the
ﬁbroblasts therapeutic. Intramyocardially injected CSp-EMVprimed (but not unprimed) ﬁbroblasts increased global pump
function and vessel density while reducing scar mass. CSp-EMV priming caused ﬁbroblasts to secrete much higher levels of
stromal-cell-derived factor 1 and vascular endothelial growth factor and dramatically changed the micro-ribonucleic acid
proﬁle of ﬁbroblast-secreted EMVs in vitro. The primingwas followed by signiﬁcant angiogenic and cardioprotective effects.
CONCLUSIONS CSp-EMVs alter ﬁbroblast phenotype and secretome in a salutary positive-feedback loop. The
phenotypic conversion of inert cells to therapeutically active cells reveals a novel mechanism for ampliﬁcation of
exosome bioactivity. (J Am Coll Cardiol 2015;66:599–611) © 2015 by the American College of Cardiology Foundation.P aracrine signaling mediates the therapeuticbeneﬁts of cardiospheres (1) and their progeny(2) (cardiosphere-derived cells [CDCs]). Extra-
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ABBR EV I A T I ON S
AND ACRONYMS
CDC = cardiosphere-derived
cell
CSp-EMV = cardiosphere-
derived extracellular
membrane vesicle
DFs = dermal ﬁbroblasts
DF-EMV = dermal ﬁbroblast-
derived extracellular
membrane vesicle
EMV = extracellular membrane
vesicle
MI = myocardial infarction
SDF = stromal-cell-derived
factor
VEGF = vascular endothelial
growth factor
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600and serve as agents of regeneration and car-
dioprotection (5,7–10); the micro-ribonucleic
acids (miRNA) within these EMVs have been
proposed to mediate the beneﬁcial effects of
CDCs after myocardial infarction (MI) (6).SEE PAGE 612Although EMV secretion is well character-
ized, the precise target cell type remains
undeﬁned. In reductionist systems, mem-
brane vesicles are known to exert direct anti-
apoptotic effects on cardiomyocytes and to
stimulate tube formation by endothelial cells
(6,8); in contrast, little is known about EMVs’
effects on ﬁbroblasts, which feature promi-
nently in scar formation and wound healing
post-MI. Herein we describe the beneﬁcialeffects of cardiosphere-derived EMVs (CSp-EMVs)
and report a novel mechanism whereby EMVs
amplify their own bioactivity: priming dermal ﬁbro-
blasts (DF) with CSp-EMVs sufﬁces to convert inert
ﬁbroblasts to therapeutically active cells in vitro and
in vivo.
METHODS
Female Wistar Kyoto rats (n ¼ 54) 5 to 6 weeks of age
were used for in vivo experiments.
Human dermal ﬁbroblasts (hDFs), human cardio-
spheres (hCSps), and human cardiosphere-derived
extracellular vesicles (hCSp-EMVs) were used for
in vitro assays. To avoid any possible confounding
effects of xenotransplantation, we used rat DFs
(rDFs) and rat CSp-EMV (rCSp-EMVs) for in vivo
experiments.
To create MIs, animals underwent permanent left
anterior descending artery ligation. Four weeks later
they underwent a second survival thoracotomy with
animals randomly assigned to intramyocardial border
zone injection using 1 of 4 treatments: 1) rCSp-EMV
derived from 2 million cells (n ¼ 16); 2) 2 million rDFs
(n ¼ 12); 3) 2 million rDFs incubated overnight with
rCSp-EMVs, then washed (rCSp-EMV DF, n ¼ 16); or
4) vehicle (phosphate-buffered saline [PBS]; n ¼ 10).
The animals were monitored for an additional 4
weeks followed by endpoint functional and histo-
logical studies.
Baseline transthoracic echocardiography was per-
formed 28 days post-MI (2 days before the second
thoracotomy). Brieﬂy, long-axis images were used
to measure left ventricular end-systolic and end-
diastolic volumes and ejection fraction. Short-
axis M-mode images at the level of the papillary
muscle were used to measure end-systolic diameter.Follow-up echocardiographic analysis was performed
4 weeks post-injections followed by euthanasia.
CDCs were isolated from male Sprague Dawley and
Brown Norway rats and cultured in Iscove’s Modiﬁed
Dulbecco’s Medium (IMDM, Life Technologies,
Carlsbad, California) supplemented with 20% fetal
bovine serum and antibiotics. To form cardiospheres,
15 million CDCs were incubated with IMDM supple-
mented with penicillin/streptomycin and 0% fetal
bovine serum in ultra-low attachment dishes. Three
days later, the conditioned medium was collected and
processed for EMV isolation (Figure 1A).
An expanded Methods section is available in the
Online Appendix.
STATISTICAL ANALYSIS. Pooled data are expressed
as mean  SE. Statistical analysis was performed us-
ing factorial analysis of variance followed by a Tukey
post-hoc analysis of mean differences or with paired
Student t test, indicated in ﬁgures by lines connecting
compared values. A value of p # 0.05 was accepted as
signiﬁcant.
RESULTS
EMV CHARACTERIZATION AND INTERNALIZATION.
EMVs were isolated from serum-free medium condi-
tioned by hCSps over a period of 3 days. The ﬁnal
pellet contained w12  109/ml of 175  12-nm diam-
eter vesicles by nanoparticle tracking analysis (3)
(NTA, NanoSight Ltd., Amesbury, Wiltshire, United
Kingdom) (Figure 1B). Flow cytometry revealed that
these vesicles expressed tetraspanins characteristic
of exosomes such as CD63, CD9, and CD81 (schematic
in Online Figure 1B and pooled data in Figure 1C).
Adding the ﬁnal pellet to hDFs resulted in vesicle
internalization as observed by confocal microscopy
(Figures 1D and 1E). For quantiﬁcation of dose-
dependent vesicle internalization, images were ob-
tained 6 (Figures 1F to 1H), 12 (Figures 1I and 1J), and
24 h (Figures 1K and 1L) after the addition of hCSp-
EMVs. Higher concentrations of added particles (20
to 40  109) resulted in signiﬁcantly higher numbers
of vesicle-laden cells, with >90% of cells positive as
early as 6 h (Figures 1G, 1I, and 1K). Individual cells
accumulate particles more rapidly at higher concen-
trations (Figures 1H, 1J, and 1L). The ﬂuorescence per
cell reached a plateau with all groups equal in in-
tensity after 24 h of incubation (Figure 1L) despite
persistent differences in percent uptake at steady
state (Figure 1K). Minimal background due to free-dye
internalization was observed in the cells incubated
with serum containing the lipophilic dye only (Online
Figure 2). Thus, at low vesicle concentrations,
cells either take up vesicles or they do not, with
FIGURE 1 CSp-EMV Characterization and Internalization
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(A) Extracellular membrane vesicles (EMVs) were isolated from cardiospheres (CSps) on day 3 post-plating by adding Exoquick precipitation solution. (B) Size distribution
was analyzed by nanoparticle tracking analysis and pooled data for particle number and size quantiﬁcation revealed an average size of 175  12-nm diameter vesicles.
(C) Tetraspanin-bound beads were used to characterize the human CSpderived EMVs (hCSp-EMVs). Representative histograms revealed expression of CD63, CD81, and
CD9. EMVs stained for tetraspanins (green line) were compared to appropriate controls (orange/blue lines). (D) Human dermal ﬁbroblasts (hDFs) were incubated with
ﬂuorescent dyed hCSp-EMVs for 24 h followed by confocal imaging. (E) z-stack image of DFs 24 h post-hCSp-EMV incubation revealed particle internalization.
(F) Representative confocal images of DFs incubated with different concentrations of hCSp-EMVs and evaluation of ﬂuorescent intensity at different time points post-
incubation revealed cells with EMV signal and EMV intensity per cell at 6 h (G and H), 12 h (I and J), and 24 h (K and L) that were dose but not time dependent. Scale
bar ¼ 250 mm; n ¼ 3-5 high-power (20) images per group. DAPI ¼ 4’,6-diamidino-2-phenylindole; DF ¼ dermal ﬁbroblast; WGA ¼ wheat germ agglutinin.
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601comparable capacities among transduced cells. This
ﬁnding provides indirect evidence against a stochas-
tic process such as membrane fusion, but is consistent
with more active mechanisms of EMV uptake (endo-
cytosis or receptor-mediated uptake).VALIDATION OF IN VITRO BIOLOGICAL ACTIVITY
OF EMVs. Experiments performed in vitro to assay
the bioactivity of hCSp-EMVs on hDFs revealed dose-
dependent suppression of phosphorylated small
mothers against decapentaplegic homolog (smad)2/3,
FIGURE 2 In Vitro Characterization of CSp-EMV Biological Activity
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Western blot of hDFs 24 h post-incubation with 2 different concentrations of hCSp-EMVs showed reduced psmad2/3 (A), psmad4 (B), and snai1 (C). Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used as a control. The experiment was performed in triplicate. Flow cytometry was used for phenotypic characterization of
the hCSp–EMVprimed ﬁbroblasts 24 h post-incubation. Representative ﬂuorescence activated cell sorting (FACS) plots (D) and pooled data (E) revealed reduced
ﬁbroblast-speciﬁc protein (FSP)-1 and discoidin domain receptor 2 (DDR2) expression while CD105 and CD90 were not affected (n ¼ 3 in each group). Confocal images of
hCSp-EMVprimed and unprimed ﬁbroblasts (F) showed enhanced density of the smooth muscle actin (SMA) cells and lower FSP1 density after CSp-EMV incubation
(G). Scale bar ¼ 250 mm. (H) Scheme of the collected supernatant after hCSp-EMVtreated ﬁbroblasts; (I) enzyme-linked immunosorbent assay (ELISA) on the collected
supernatant revealed increased levels of SDF-1 and VEGF in the post-primed ﬁbroblasts. n ¼ 5 per group. *p < 0.05 versus unprimed ﬁbroblasts. FACS ¼ ﬂuorescence
activated cell sorting; ISO ¼ isotype control; smad ¼ small mothers against decapentaplegic homolog; other abbreviations as in Figure 1.
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603smad4, and snai1, a zinc ﬁnger transcription factor
and master regulator of epithelial-mesenchymal
transition (Figures 2A to 2C). These antiﬁbro-
tic signaling changes mirror those described for
CSp-conditioned media (11). To look for potential
conversion of ﬁbroblast phenotype, we evaluated the
expression of ﬁbroblast-speciﬁc protein 1 (FSP1), dis-
coidin domain receptor 2 (DDR2), CD105, and CD90,
after 24 h of hCSp-EMV incubation. Representative
ﬂow cytometry plots (Figure 2D) and pooled data
(Figure 2E) reveal signiﬁcant attenuation of both FSP1
and DDR2, but no effects on CD105 or CD90 expres-
sion after single exposures to hCSp-EMVs. Immuno-
histochemistry conﬁrmed the reduced expression of
FSP1, but also showed enhanced expression of
smooth muscle actin (SMA) (Figures 2F and 2G). The
secretome of hDFs also changed after exposure to
hCSp-EMVs: primed hDFs secreted much higher
levels of stromal-cell-derived factor 1 (SDF-1) and
vascular endothelial growth factor (VEGF) than
unprimed hDFs (Figures 2H and 2I). Both changes are
salutary in the post-MI setting, insofar as SDF-1 pro-
motes homing and activation of endogenous stem
cells (13), whereas VEGF stimulates angiogenesis (1).
Similar changes were seen in hDFs treated with CSp-
exosomes isolated by ultracentrifugation (Online
Figure 3A), a complementary isolation method to
the default precipitation approach. Ultracentrifuga-
tion enriches EMVs and particularly exosomes while
excluding protein complexes and other debris (12).
The congruence of the ﬁndings with the 2 isolation
methods supports the conjecture that EMVs, and
particularly exosomes, are primarily responsible for
the biological effects investigated here.
CARDIOPROTECTIVE AND ANGIOGENIC EFFECTS OF
hCSp-EMVLPRIMED DFs. Conditioned media from
hCSp-EMVprimed hDFs and hCSp-EMVs per se
reduced cardiomyocyte apoptosis after oxidative
stress, unlike hDF-EMVs (representative ﬂuorescence
activated cell sorting [FACS] plots in Figure 3A to 3C
and pooled data in Figure 3D). Additionally, in an
in vitro matrigel angiogenesis assay, conditioned
media from hCSp-EMVprimed DFs exerted an
angiogenic effect, which was as strong as that of
hCSp-EMV alone; both treatments induced signiﬁ-
cantly more tube formation than hDF-EMVs (repre-
sentative microscope images in Figures 3E to 3G and
pooled data in Figure 3H). Thus, hCSp-EMV priming
confers on hDFs the ability to stimulate angiogenesis
and to protect cardiomyocytes against stress-induced
apoptosis. Enhanced angiogenesis was also observed
using hCSp-exosomes isolated by ultracentrifugation
(Online Figures 3B to 3D), once again indicating that apreparation enriched in exosomes can recapitulate
the beneﬁcial effects seen with EMVs isolated by
precipitation.
DISTINCTIVE miRNA PROFILES OF hCSp-EMVL
PRIMED DFs. We previously reported that hCDC-
derived EMVs, identiﬁed as exosomes, express a
unique miRNA payload that at least partially accounts
for the in vivo regenerative capacity of CDCs (6).
Indeed, this and other reports have led to the
conjecture that vesicles affect gene expression of
recipient cells by miRNA transfer (14–16). To see if
this mechanism might be operating here, we ﬁrst
investigated the global miRNA content of hCSps and
compared it to that of hDFs. A number of miRNAs
were enriched in hCSps relative to hDFs: Figure 4A
highlights those that are most abundantly overex-
pressed in hCSps. We then compared the miRNA
proﬁles of CSp-EMVprimed and unprimed hDFs.
Figure 4B reveals that hCSp-EMVprimed hDFs
express very different miRNAs than unprimed hDFs
(Figure 4B). The pattern only partially resembles that
of the cells of origin (hCSps; compare to Figure 4A) or
of the vesicles secreted by hCSps (Figure 4C), hinting
that simple passive transfer of vesicular miRNAs
cannot fully account for the distinctive miRNA proﬁle
of hCSp-EMVprimed hDFs. Finally, we compared
the miRNA proﬁles of vesicles secreted by primed and
unprimed hDFs by collecting media produced 24 h
after priming by hCSp-EMVs or vehicle. The miRNA
proﬁles of primed and unprimed hDFs differed
enormously (Figure 4D). The miRNAs secreted by
hCSp-EMVprimed hDFs include several that are
enriched in hCSp-EMVs themselves (notably miRNA-
146a, which was highlighted by Ibrahim et al. (6)
and is elevated in all therapeutically active groups
here), but the patterns are otherwise quite individ-
ual. Thus, priming with hCSp-EMVs leads to fun-
damental changes in hDF miRNA expression proﬁles
and hDF-secreted vesicles. The distinctive miRNA
proﬁles in hCSp-EMVprimed hDFs and their
membrane vesicles argue against the possibility that
the changes merely reﬂect accumulation and sub-
sequent “regurgitation” of miRNAs transferred in
hCSp-EMVs.
rCSp-EMVLPRIMED FIBROBLASTS REVERSE REMODELING.
We have presented evidence that hCSp-EMVprimed
hDFs secrete SDF-1 and VEGF, exert anti-apoptotic
and angiogenic effects in vitro, and express distinc-
tive miRNAs. Therefore, we questioned whether
rCSp-EMVs themselves, as well as rCSp-EMVprimed
DFs, might confer therapeutic beneﬁts in vivo in a rat
model of chronic MI. One month after permanent left
anterior descending ligation, animals underwent
FIGURE 3 In Vitro Bioactivity of CSp-EMVPrimed Fibroblasts
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Representative FACS plots of neonatal rat ventricular myocytes (NRVMs) treated with (A) hDF-EMVs, (B) conditioned media from hCSp-EMV
primed hDFs, and (C) hCSp-EMVs for 72 h and stained with Annexin V to evaluate apoptosis. The experiment was performed in triplicate (n ¼ 3
for each group). (D) Pooled data for the NRVM apoptosis revealed higher viability in the hCSp-EMVprimed ﬁbroblast and hCSp-EMVs groups
compared to the DF-EMVs. (Histogram color ¼ group in bar graph.) (E to G) Representative higher power images of the matrigel tube formation
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bar ¼ 50 mm. Abbreviations as in Figures 1 and 2.
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FIGURE 4 miRNA Array Analysis: Signature of Secreted Extracellular Vesicles and Parent Cells
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605intramyocardial injection. To assess particle bio-
distribution qualitatively, animals (n ¼ 3) injected
with dye-labeled rCSp-EMVs were euthanized 1 h
post-injection and selected organs were imaged.
Approximately 20% of the injected rCSp-EMVs were
found in the heart; the lungs also exhibited obvious
uptake, with less in other organs (Online Figure 4).
This percentage of retention in the heart at 1 h com-
pares favorably with that seen with intramyocardiallyinjected cells (17). Minimal intensity was detected
after the free dye control injections only (data not
shown).
For long-term physiological experiments, animals
were randomly allocated to 1 of the following 4
groups: vehicle (PBS), unprimed rDFs, rCSp-EMVs,
or rCSp-EMVprimed rDFs with treatment at 1
month post-MI (Figure 5A). One month later, echo-
cardiography revealed improved ejection fraction in
FIGURE 5 In Vivo Studies
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According to the study timeline (A), myocardial infarction was induced in Wistar Kyoto rats; 1 month later, the animals were allocated to injection of vehicle (PBS; orange;
n ¼ 6), rDFs (blue; n ¼ 8), rDFs primed with rCSp-EMVs (grey; n ¼ 8), or rCSp-EMVs only (purple; n ¼ 8). Functional follow-up and histological analysis were performed
1 month post-injection. At 1 month post-injection, rCSp-EMVs and rCSp-EMVprimed rDFs showed signiﬁcant improvement in cardiac function via ejection fraction (B) as
well as better-maintained left ventricular end-systolic diameter (LVESD) via M-mode short-axis images (C) compared to control groups. Scar mass was evaluated by
serial Masson’s trichromestained sections from the left ventricle (D), and was signiﬁcantly reduced in the rCSp-EMVs and the rCSp-EMVprimed rDF groups compared
to either control group (E). Signiﬁcant differences also were observed in infarct wall thickness (F). *p < 0.05 versus DFs; **p < 0.05 versus PBS. PBS ¼ phosphate-
buffered saline; rCSp ¼ rat cardiosphere; rDF ¼ rat dermal ﬁbroblast; other abbreviations as in Figure 1.
Tseliou et al. J A C C V O L . 6 6 , N O . 6 , 2 0 1 5
Fibroblast Conversion by Extracellular Vesicles A U G U S T 1 1 , 2 0 1 5 : 5 9 9 – 6 1 1
606the rCSp-EMVs and the rCSp-EMVprimed rDFs
groups compared to either vehicle or unprimed rDFs
(Figure 5B). This ﬁnding primarily reﬂected differ-
ences in left ventricular end-systolic diameter
(Figure 5C). Histological analysis (of samples exem-
pliﬁed in Figure 5D) showed signiﬁcant reductions in
scar mass (Figure 5E) and enhanced infarct wall thick-
ness (Figure 5F) in the rCSp-EMVs and rCSp-EMV
primed rDF groups. The structural and functional
improvements seen with rCSp-EMVs and rCSp-
EMVprimed rDFs were comparable to those reported
with rCSp injection in this model (11).
Finally, to test the in vivo angiogenic capacity of
CSp-EMVs and CSp-EMVprimed cells, we quantiﬁed
capillaries (bounded by von Willebrand factor
positive cells) and microvessels (bounded by SMA-
positive cells) (Figure 6A). Analysis of serial images
from the apex to the base revealed greater capillary
density in the rCSp-EMVs and rCSp-EMVprimed
groups compared to both controls in all 3 zones
evaluated (infarct, border, and remote) (Figures 6Bto 6D, left panel). Microvessel density was likewise
increased, but only in the infarct zone (Figures 6B to
6D, right panel). Another mechanism underlying CSp
regenerative efﬁcacy is cardiomyocyte proliferation
(13,18). Bromodeoxyuridine incorporation revealed
enhanced deoxyribonucleic acid synthesis after
exposure to rCSp-EMVs and rCSp-EMV-rDFs compared
to PBS and unprimed rDFs, validating previous reports
(6) (Online Figures 5A and 5B). Interestingly, this effect
tended to be more prominent after rCSp-EMVonly
injections compared to rCSp-EMV-rDFs. Finally, no
changes in cardiomyocyte diameter were observed
(Figures 7A to 7C).
DISCUSSION
We have observed remarkable effects of EMVs from
hCSps on ﬁbroblasts. DFs are venerable controls for
cardiac cell therapy; their injection neither improves
nor aggravates adverse remodeling after MI (1,19). DF-
produced exosomes are likewise inert (6). In contrast,
FIGURE 6 In Vivo Vessel Density 1 Month Post-Treatment
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(A) Representative immunostained images from the infarct, border, and remote zones are presented for evaluation of microvessel and capillary density. In the infarct (B),
border (C), and remote (D) zones, pooled data revealed enhanced von Willebrand factor (vWf)positive capillary density in the rCSp-EMVs and rCSp-EMVprimed
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607cardiospheres and their progeny trigger functional
recovery and structural improvements in various
ischemic and nonischemic models of heart failure
(20–22). This beneﬁcial effect was recently attributed
to secreted exosomes (6). Although interaction of
EMVs with endothelial cells and cardiomyocytes has
been reported (5,6,23,24), our data support a strong,
previously unappreciated bioactivity of CSp-EMVs
on ﬁbroblasts and other cardiac cell types (Central
Illustration). More speciﬁcally, we report that, in the
restricted environment of in vitro priming with hCSp-
EMVs, hDFs exert a dose-dependent downregulation
of the transforming growth factorb cascade andincreased secretion of SDF-1 and VEGF. Remarkably,
these primed ﬁbroblasts promote angiogenesis and
inhibit cardiomyocyte apoptosis in vitro, whereas
in vivo they can attenuate remodeling and improve
function to levels equivalent to those reported with
rCSps (11).
Vesicular transfer of miRNAs mediates cell-cell
communication in different biological systems
(25–27). However, the miRNA cargo of EMVs does not
necessarily reﬂect passive loading with RNAs in the
parent cell; selective enrichment mechanisms appear
to be at play (15). This selective miRNA payload may
be a crucial determinant of bioactivity on the
FIGURE 7 In Vivo Cardiomyocyte Architecture 1 Month Post-Therapy
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608recipient population. Indeed, we found a distinct
miRNA signature in primed versus unprimed hDFs
that does not reﬂect passive release of internalized
hCSp-EMVs. Therefore, internalization of hCSp-EMVs
leads to downstream, biologically signiﬁcant changes
in miRNA vesicular cargo released by the recipient
hDFs. Additionally, because ﬁbroblast-derived EMVs
enriched in miRNAs do not improve recovery in vivo
(28), the cargo transition described here may provide
promising clues to pathways involved in reverse
remodeling.
Many studies report an innate plasticity of ﬁbro-
blasts that allows them to acquire a cardiomyocyte orendothelial phenotype after exposure to either tran-
scription factors or small molecules (29–32). These
direct reprogramming approaches may constitute
a promising therapeutic strategy (33). Our data
indicate that single-dose priming with CSp-EMVs
converted DFs to a less ﬁbrotic phenotype with
functional properties equal to those of CSp-EMVs.
Interestingly, the transforming growth factorb
pathway, which provides key signals in cellular
conversion (34,35), was signiﬁcantly downregulated
(Figures 2A to 2C). We do not yet know if EMVs or
an EMV subgroup (e.g., exosomes) sufﬁce to
durably reprogram DFs to a fully-distinct cell type,
CENTRAL ILLUSTRATION Conversion of Inert Fibroblasts to Active Cells
Tseliou, E. et al. J Am Coll Cardiol. 2015; 66(6):599–611.
Cardiosphere-derived exosomes were used to prime inert ﬁbroblasts. Post-priming analysis of ﬁbroblast bioactivity revealed ampliﬁcation of their therapeutic properties
including cardiomyogenic, angiogenic, antiﬁbrotic, and regenerative effects.
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609but our data do indicate that inert ﬁbroblasts can
be functionally converted both in vitro and in vivo
for a sufﬁcient duration to shape therapeutic
activity.
Crosstalk between endothelial cell-derived vesicles
containing miRNAs and the surrounding myocardium
has been reported (24). Here we showed that, beyond
strictly paired cell-cell communication, divergent
transportation of biologically signiﬁcant signals
takes place between hCSp-EMVprimed DFs and
recipient human umbilical vein endothelial cells or
cardiomyocytes. These ﬁndings in culture may help
to rationalize the efﬁcacy of a relatively low number
of cells injected in vivo: transplanted cells secrete
EMVs, which interact with the surrounding tissue and
convert it into a more salutary milieu, in a positive
feedback loop (2,36).
Xenogeneic transplantation of CSps post-MI elicits
detrimental immunological sequelae, although allo-
geneic CSps are effective and immunologically innoc-
uous (2). Here we used allogeneic rCSp-EMVs to
evaluate potency in vivo and allogeneic hCSp-EMVs
for in vitro experiments. Evaluation of the immuno-
logical sequelae of allogeneic and xenogeneic EMVs isbeyond the scope of the present study, but it seems
likely that CSp-EMVs may be even less immunogenic
than CSps, as they express far fewer surface antigens
and, unlike cells, cannot react dynamically to immu-
nological cues.
STUDY LIMITATIONS. The cardiovascular ﬁeld has
previously tended to focus on exosomes, rather than
EMVs as a whole (37,38). Exosomes, nano-sized par-
ticles produced by the endolysosomal pathway, are
but one class of EMVs (39). The isolation method used
here relies on precipitation by polyethylene glycol,
which pulls down all EMVs, not just exosomes, and
also macromolecules including RNA-protein com-
plexes (39,40). Thus, it is possible that some of our
results might be attributable to larger, biologically
distinct microvesicles or apoptosomes or even to non-
EMV entities (e.g., free RNA or protein). Nevertheless,
the size distribution (Figure 1B), antigenic composi-
tion (Figure 1C), and contents (Figure 4) of our default
preparations are most consistent with a preponder-
ance of exosomes (41). Key phenotypic changes are
recapitulated by EMVs isolated by ultracentrifugation
(Online Figure 3), the gold standard method for
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
CSp-EMVs and particularly their exosomes convert
inert dermal ﬁbroblasts into therapeutically active
cells capable of decreasing scar and improving func-
tion in a chronic myocardial infarction model. This
represents a mechanism of ampliﬁcation whereby
a small number of transplanted cells can exert wide-
spread, durable beneﬁts in injured myocardium.
TRANSLATIONAL OUTLOOK: Further animal and
clinical experiments are warranted to explore the
potential therapeutic roles of CSp-EMVs and
CSp-EMVprimed ﬁbroblasts for diseases in which
scar reduction, angiogenesis, and cardiomyocyte
proliferation could be beneﬁcial.
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610enriching exosomes (12), further implicating exo-
somes as mediators of the beneﬁcial effects.
CONCLUSIONS
CSp-EMVs alter ﬁbroblast phenotype and secretome in
a salutary positive-feedback loop: exposure of “inert”
ﬁbroblasts to CSp-EMVs rendered the ﬁbroblasts
therapeutic. Intramyocardially injected CSp-EMV
primed (but not unprimed) ﬁbroblasts increased global
pump function and vessel density while reducing scar
mass. The phenotypic conversion of inert cells to
therapeutically active cells reveals a novel mechanism
for ampliﬁcation of exosome bioactivity.
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